1. Home
  2. DSP vs STTK Comparison

DSP vs STTK Comparison

Compare DSP & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viant Technology Inc.

DSP

Viant Technology Inc.

HOLD

Current Price

$11.77

Market Cap

184.3M

Sector

Technology

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$3.05

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DSP
STTK
Founded
1999
2016
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
184.3M
119.0M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
DSP
STTK
Price
$11.77
$3.05
Analyst Decision
Strong Buy
Buy
Analyst Count
8
5
Target Price
$18.50
$4.00
AVG Volume (30 Days)
262.0K
392.9K
Earning Date
11-10-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
29.49
N/A
EPS
0.10
N/A
Revenue
$324,131,000.00
$1,000,000.00
Revenue This Year
$17.79
N/A
Revenue Next Year
$17.72
N/A
P/E Ratio
$119.42
N/A
Revenue Growth
22.97
N/A
52 Week Low
$8.11
$0.69
52 Week High
$26.33
$3.38

Technical Indicators

Market Signals
Indicator
DSP
STTK
Relative Strength Index (RSI) 60.87 67.21
Support Level $11.10 $2.82
Resistance Level $12.26 $3.30
Average True Range (ATR) 0.50 0.24
MACD -0.03 -0.00
Stochastic Oscillator 56.45 74.76

Price Performance

Historical Comparison
DSP
STTK

About DSP Viant Technology Inc.

Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: